The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
van Dijk, Marianne Murphy, Eoin Morrell, Ruth O'Dwyer, Michael Szegezdi, Eva Samali, Afshin
van Dijk, Marianne
Murphy, Eoin
Morrell, Ruth
O'Dwyer, Michael
Szegezdi, Eva
Samali, Afshin
Loading...
Publication Date
2011
Keywords
Type
Article
Downloads
Citation
van Dijk M, Murphy E, Morrell M , Knapper S , O'Dwyer M, Samali A, Eva Szegezdi E. (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis'. Cancers, 3 :1329-1350.
Abstract
Acute myeloid leukemia (AML) is an aggressive stem cell malignancy that is difficult to treat. There are limitations to the current treatment regimes especially after disease relapse, and therefore new therapeutic agents are urgently required which can overcome drug resistance whilst avoiding unnecessary toxicity. Among newer targeted agents, both tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and proteasome inhibitors show particular promise. In this report we show that a combination of the proteasome inhibitor bortezomib and TRAIL is effective against AML cell lines, in particular, AML cell lines displaying myelomonocytic/monocytic phenotype (M4/M5 AML based on FAB classification), which account for 20-30% of AML cases. We show that the underlying mechanism of sensitization is at least in part due to bortezomib mediated downregulation of c-FLIP and XIAP, which is likely to be regulated by NF-kB. Blockage of NF-kB activation with BMS-345541 equally sensitized myelomonocytic AML cell lines and primary AML blasts to TRAIL.
Funder
Publisher
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland